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A B S T R A C T Acute clearance studies were performed in stable thyroparathyroidectomized dogs to evaluate the possibility of a direct renal action of vitamin D and its biologically active 25-hydroxylated metabolite. Alterations in renal hemodynamics and serum calcium concentration were minimized and attempts at vitamin D depletion were not undertaken. Steady-state volume expansion of modest degree was employed as the control experimental situation so that an effect of the vitamin to enhance phosphate reabsorption would not go undetected because of an already maximal phosphate reabsorptive rate secondary to, parathyroidectomy. Under these experimental circumstances, 10,000 U of cholecalciferol and 25-120 U of 25-hydroxycholecalciferol (25- HCC) produced significant depressions in the percentage of filtered phosphate excreted (mean declines of 39 and 47%, respectively), which were not attributable to alterations in renal hemodynamics or to changes in the levels of serum calcium or phosphate. There was an accompanying decline in sodium and calcium excretion; mean percentage excretion rates for sodium fell by 38% with vitamin D and 26% with 25HCC, and for calcium this measurement declined by 46 and 23%, respectively.
Furthermore, parathyroid hormone and 25HCC produced antagonistic effects on phosphate excretion. These observations provide the first conclusive evidence for a direct (proximal) tubular action of vitamin D to promote phosphate (as well as sodium and calcium) transport.
This work was presented in part to the Fourth Annual
INTRODUCTION
Investigations of the biological effects of vitamin D have been devoted largely to evaluations of its action on the skeleton and gastrointestinal tract. While not entirely ignored, the possibility of an additional effect of the vitamin on the transport of electrolytes by the kidney has been considered at the very least substantially unproven, and at best, controversial (1) (2) (3) (4) (5) (6) . This relative dearth of experimental inquiry as regards vitamin D and the kidney is all the more remarkable in view of the numerous suggestions from the clinical literature that, in fact, the vitamin might possess a renal action (7) (8) (9) (10) (11) . Those reports which are available regarding alterations in renal phosphate (and calcium) reabsorption secondary to an action of the vitamin are difficult to interpret for one or more of the following reasons. First, in intact animals, there is the distinct possibility that the changes noted could have resulted from variations in circulating levels of parathyroid hormone (PTH)' and/or thyrocalcitonin (7, 11, 12 ). Secondly, the absolute level of the serum calcium concentration and the degree of vitamin D depletion appear to be important in and of themselves in establishing the level of excretion of phosphate by the kidney (13) (14) (15) (16) . Third, the employment of chronic periods of study allows time for other homeostatic mechanisms involved in calcium and phosphorous metabolism to come into play and renders difficult the separation of any renal effects of the vitamin from those on bone and gut (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) 17) ; and, finally, there is evidence that variations in renal hemodynamics can produce major changes in the excretion of calcium and phosphate (18) (19) (20) (21) (22) .
So that these impediments to data interpretation could be obviated, the studies to be described were conducted in stable thyroparathyroidectomized (TPTX) animals. Acute rather than chronic studies of vitamin D3 (cholecalciferol) and 25-hydroxycholecalciferol (25-HCC) effects on nephron function were studied and no attempt was made to deplete the animals of vitamin D. Additionally, any potential effects of alterations in serum calcium concentration, glomerular filtration rate (GFR), and renal plasma flow on the experimental observations obtained were minimized.
The possibility has been entertained on numerous occasions that there might be important differences between the effects of physiologic as compared to pharmacologic doses of vitamin D (1, 5) . The discovery, isolation, and recent availability of synthetic 25HCC (23, 24) , an important biologically active metabolite of the parent compound, with demonstrated effectiveness on bone and gut (25, 26) has allowed us -to substantially reduce the amount of material employed in studying the relationship of vitamin D to renal electrolyte transport. Because of the important actions of PTH and extracellular fluid volume status on renal transport (18, 27) , the interactions of these agents with that of 25HCC on the kidney were also investigated. METHODS 28 acute clearance studies were performed on TPTX female mongrel dogs weighing [18] [19] [20] [21] [22] [23] kg. Completeness of the removal of the parathyroid glands was verified by determination of the serum calcium concentration 2-4 days postoperatively, and just before each study. Animals were selected for study only if there had been at least a 30% fall in serum calcium concentration. Several of the animals developed tetany which was treated with parathyroid extract or calcium infusion, or both. When this occurred, no animal was utilized for study within 48 hr of the cessation of such therapy, and most often, at least a week elapsed during which neither agent was administered before a study was attempted. The animals were allowed to recover from the neck surgery for at least 3 days, and usually 6-7 days before clearance experiments were performed. They were maintained on a diet adequate in calcium, phosphorous, sodium, and potassium and were given 100 mg of synthyroid or 60 mg of desiccated thyroid every other day.
Experimental protocol. The animals were fasted and thirsted for 16 hr before the study and received 1 cc of vasopressin tannate in oil (pitressin, Parke, Davis & Co., Detroit, Mich.) the evening before the experiment. Light anesthesia was induced with sodium pentothal (25 mg/kg) and maintained by the subsequent intermittent injection of supplemental doses. A cuffed endotracheal tube was inserted and the animals were ventilated with a Harvard respirator. (29), respectively. Total serum and urine phosphate were analyzed by the method of Fiske and Subbarow (30) adapted to the AutoAnalyzer.
The percentage of filtered sodium, potassium, calcium, and phosphate appearing in the urine was determined from the ratio of the clearance of each ion to that of inulin, multiplied by 100.
Standard statistical methods were employed (31). Table I summarizes the data for both the control studies (group A) and for those experiments in which either vitamin D3 (group B) or its 25-hydroxylated metabolite was administered intravenously in graded dosage (groups C, D, and E). In Table II Serum ultrafilterable calcium showed no consistent change in any of the groups studied and the mean arterial blood pressure monitored in a few experiments showed no tendency towards any consistent variation. In preliminary studies performed to establish a dosage of vitamin D3 which would produce a consistent effect on phosphate excretion, a range of 100-5000 U of this substance was found to be ineffective (data not shown).
RESULTS
The relationship of the changes in phosphate transport to those of calcium and sodium are depicted in Fig. 1 for both the control studies (open symbols) and those experiments in which 25HCC was administered (closed symbols). These data, plotted for each of the ions as changes in the percentage of filtered load excreted into the urine demonstrate the following. First, the control studies can be separated from the 25HCC experiments in that in the former, no change or an increase in percentage phosphate excretion occurred, while in the latter, depressions in phosphate excretion invariably resulted. Secondly, for the most part the changes in sodium and calcium excretion followed, in direction, those for phosphate. And third, in a general way, the greater the change in phosphate excretion the greater the alteration also in the transport of sodium and calcium, regardless of whether one examines the data from the control animals or from the 25HCC studies.
The data were also analyzed with regard to the time sequence of the alterations in phosphate transport induced by vitamin D3 and its 25-hydroxylated metabolite. In Fig. 2 the chronologic course of events after the administration of these compounds is compared to the pattern of phosphate transport obtained in the control studies. Maintenance of the modest saline expansion employed in these experiments can be seen to have resulted in a mildly, ever-increasing phosphaturia as the experiments continued. Cholecalciferol produced a fall in phosphate excretion with an onset at about [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] min, whereas the action of 25HCC became evident at 3040 min and peaked at about 90-120 min. Thus, not only was approximately 100-400 times as much of the parent compound required to induce changes in electrolyte transport, but these changes were of smaller magnitude than those induced by the small amounts of the metabolite employed. Furthermore, administration of 25HCC shortened the lag time of response demon- Combination experiments. The effect of 25HCC on the well known phosphaturic action of PTH was evaluated by superimposing the administration of each of these agents on the other. In Fig. 3 Reversal of the sequence of administration of these two agents resulted in the data shown in Fig. 4 . In three experiments, the infusion of 25HCC at [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] U/hr reversed the phosphaturia due to PTH when the hormone was given at rates of 10-30 U/hr; however at higher dosage levels of PTH (50-60 U/hr) the phosphaturic action of the hormone continued unperturbed despite the addition of 25HCC. Determinations of GFR and renal plasma flow in these combination experiments revealed that the alterations in phosphate excretion induced by PTH and 25HCC could not be accounted for on the basis of variations in renal hemodynamics.
DISCUSSION
The studies herein reported were performed with the objective of evaluating any potential effect of vitamin D on the kidney in the absence of uncontrolled factors which could make interpretation of the experimental observations difficult or impossible. To this end, the following steps were taken. First, all of the experiments were undertaken in animals in which complete ablation of the thyroid and parathyroid glands had been accomplished and the animal had been allowed to achieve a state of stable hypoparathyroidism. Hypothyroidism was averted by replacement therapy. Secondly, because in the parathyroidectomized animal, phosphate excretion is frequently so low as to defy accurate measurement, steady-state volume expansion, a well known phosphaturic maneuver (18, 21, 27) , was employed as the control experimental situation. Furthermore, we selected as our expanding volume an amount of saline (25 ml/kg body weight) which has been demonstrated to inhibit electrolyte transport mainly in the proximal tubule, without major effects on the distal nephron (18, 27 In the present series of experiments, the intravenous infusion of 10,000 U of vitamin Di resulted in a mean depression of phosphate excretion of 39% from control levels, with a concomitant decrease in the excretion of sodium and calcium. This dosage of the vitamin was arrived at by an evaluation of the effects of a wide range of doses (100-10,000 U) on phosphate excretion. Only at the 10,000 U level was there a consistent and reproducible effect of cholecalciferol within the 2-3 hr period of observation employed. The administration of 25-120 U of 25HCC likewise produced an invariable fall in the percentage of filtered phosphate which appeared in the urine (mean decrease of 47%), and also induced a small but significant decline in the percentage excretion rates of sodium and calcium (Table I and Fig. 1 ). These actions of both the parent vitamin and its active metabolite could be shown not to be attributable either to alterations in renal hemodynamics or to changes in the concentration of serum ultrafiltrable calcium since these (latter) parameters showed no consistent variation whereas phosphate excretion fell in each study. Thus, the action of cholecalciferol and that of its 25-hydroxylated metabolite on electrolyte transport would appear to be the result of a direct tubular effect. Furthermore, not only was as little as 25 U of 25HCC effective in enhancing the reabsorption of phosphate, but it was capable of antagonizing the phosphaturic action of volume expansion in so doing.
There is presently available a large body of data obtained both from clearance and micropuncture investigations which strongly suggests that phosphate is 380 handled in the kidney by the processes of filtration at the glomerulus and then tubular reabsorption (18, 27, 33-39). Conclusive evidence for net phosphate secretion has not been forthcoming. Furthermore, the majority of micropuncture investigations in the rat (36, 38, 39) , as well as those in the dog (18, 27) , have demonstrated that phosphate reabsorption has either been completed, or else is virtually complete, by the time the tubular fluid leaves the proximal convoluted tubule. Additionally, a major proportion of filtered sodium and calcium (of the order of 70-80%) is reabsorbed in the proximal nephron (19, (40) (41) (42) (43) . Therefore, in the mammalian kidney, the proximal nephron serves as a major site for both sodium and calcium reabsorption and represents probably the sole locus of phosphate transport. Rarely, if ever, do agents which alter the transport of one ion have no effect on the reabsorption of others. Thus, for example, saline expansion can be shown to inhibit not only sodium transport but that of phosphate (18, 21, 27) and calcium (19, 20, 44, 45) as well. In addition, there are data available which indicate that when maneuvers are performed which enhance rather than inhibit fractional reabsorption, the transport of these three ions is affected similarly (18, 20, 21, 46 (52, 53) . This process occurs primarily, if not entirely, in the kidney (54, 55) , and 1,25DHCC has been shown to enhance the absorption of calcium from the gut contents (56) (57) (58) Previous studies of the effect of vitamin D on renal electrolyte transport have produced conflicting results. To a large extent, the controversy surrounding these experimental observations is the result of the fact that there exist multiple defects in experimental design which render meaningful interpretation of the data difficult. The landmark experiments of Harrison and Harrison (7), which originally suggested the possibility of a direct renal action of vitamin D, have been criticized on the basis that they were performed in intact animals so that the effect of varying PTH levels on urinary phosphate excretion related to vitamin D-induced elevations in serum calcium cannot be separated from a direct renal action of the vitamin. Similar objections can be leveled at studies in rachitic children, such as those by Klein and Gow (12) in which vitamin D in rather large doses seemed to improve phosphate reabsorption. An additional problem which complicates the interpretation of previous studies is the effect which changes in renal hemodynamics introduce. Thus, marked elevations in serum calcium have been shown to produce reductions in GFR and renal blood flow (22) which can lead to a depression of the urinary excretions of calcium, sodium, and phosphate. This fact must be taken into consideration in evaluating the studies of Gran, who noted an enhanced calcium reabsorption in rachitic puppies after vitamin D administration for several days (14) and in the interpretation of the chronic studies performed in the rachitic dog by Ney, Kelly, and Barrter (15) . Investigations performed in TPTX animals are subject to yet another criticism; that is, the existence of a base line phosphate excretion before administration of the vitamin which is very low will preclude the identification of an antiphosphaturic effect of vitamin D. Such a situation exists in the acute studies of Ney et al. in the dog (15) and those of Crawford, Gribetz, and Talbot in the rat (13) . In both of these investigations the administration of vitamin D to very recently PTX animals with tubular phosphate reabsorption of better than 98% resulted in no detectable alteration in phosphate excretion. Finally, the chronic administration of large doses of vitamin D may produce a mild hypercalcemia which has been shown to inhibit the tubular reabsorption of both sodium and phosphate (60) . This observation could explain the phosphaturia which developed in the chronic studies of Crawford et al. (13) .
When these methodological problems are taken into consideration, there remains experimental evidence which would appear to support our results. Thus, Clark and Rivera-Cordero found that the urinary phosphate actually decreased both in intact and parathyroidectomized rats given 2500 U of vitamin D daily for 12 days, while serum calcium rose only from 3.55 to 4.06 mEq/liter-levels not expected to cause a diminished GFR-although such data are not given (17) . In addition, Gekle, Strdder, and Rostock found an enhancement of phosphate reabsorption by vitamin D in the first 3 hr after the onset of its administration (39) . This occurred both in normal and rachitic rats and the effect was found to be independent of changes in GFR and serum calcium concentration.
With the exception of those studies in which only 25 U of 25HCC was utilized, the dosage of vitamin D and its metabolite employed in previous studies as well as those herein reported no doubt are in the pharmacologic range. Thus, despite having shown a direct tubular effect of vitamin D on renal phosphate reabsorption there remains the question of the importance of this phenomenon physiologically. In this regard, there are available in the clinical literature several studies which provide indirect evidence in favor of this postulate (8) (9) (10) (11) (12) . Harrison and Harrison were originally prompted to open the question of a renal action of vitamin D because of their observation that it was not possible for them to account for the hypophosphatemia encountered in some of the rachitic infants under study in their metabolic unit merely on the basis of gut loss (7) . It was their observation that the low phosphate level of such patients was the result of the paradoxical loss of phosphate in the urine, and that this phosphaturia could be corrected by the administration of vitamin D (61). However, secondary hyperparathyroidism is well known to be a frequent, if not invariable, concomitant of vitamin D deficiency rickets (62) (63) (64) . Therefore, theoretically the phosphaturia might represent the hypersecretion of PTH, and the reduction in the phosphaturia after vitamin D administration could be attributed to suppression of PTH elaboration by an elevation in serum calcium concentration resulting from enhancement by vitamin D of gut absorption of calcium. To counter the latter argument, one would have to demonstrate an improvement in renal phosphate reabsorption before any change in serum PTH levels, or, lacking this assay, at least before any alteration could be noted in the serum calcium level. Now that reliable PTH assays have become available, what is lacking are cases of vitamin D deficiency rickets, which has apparently almost disappeared from the American medical scene. However, there are several cases available in the literature in which serum phosphate rose (and, frequently, in which urine phosphate declined) after vitamin D administration, while no change, or even a fall in serum calcium concentration was occurring (8) (9) (10) (11) .
To the best of our knowledge, the observations reported here represent the first clear cut evidence for enhancement of phosphate (as well as sodium and calcium) reabsorption in the proximal tubule of the intact organism by any humoral or chemical agent. The implications of these data for the study of disease states such as hypophosphatemic rickets are obvious. Investigations aimed at evaluating the physiological significance of this phenomenon in both the experimental and human situations are now in progress.
